Table 1.
Benign | Malignant | |
Gender | ||
M | n = 38 (88.4%) | n = 102 (81.0%) |
F | n = 5 (11.6%) | n = 24 (19.0%) |
Age | 54.5 years (17–73 years) | 60.7 years (25–85 years) |
Grade | ||
1 | N/A | n = 33 (26.2%) |
2 | N/A | n = 58 (46.0%) |
3 | N/A | n = 35 (27.8%) |
Stage | ||
T1 | N/A | n = 65 (38.5%) |
T2 | N/A | n = 38 (22.5%) |
T3 | N/A | n = 20 (11.8%) |
T4 | N/A | n = 3 (1.8%) |
Pathology | Inflammation, n = 24 (55.8%) | UC, n = 125 (99.2%) |
Hyperplasia, n = 11 (25.6%) | Undifferentiated carcinoma, n = 1 (0.8%) | |
Normal, n = 6 (14.0%) | ||
Pheochromocytoma, n = 2 (5.7%) |